Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

313.98 12.31 −3.77%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 281.96
P/S ratio
2.46 2.10 2.72 3.55
P/FCF ratio
19.07 21.58 29.39 35.29
P/Operating CF
67.02 205.57 60.60 55.50
P/B ratio
3.12 2.87 3.83 4.36
EV/Sales
2.94 2.71 3.33 4.11
EV/EBITDA
19.90 18.65 24.09 29.56
EV/FCF
22.78 27.90 35.94 40.91
Current Ratio
1.29 1.36 1.35 1.41
Net Debt/EBITDA
(47.87) 13.21 12.97 0.00
Debt/Equity
0.67 0.90 0.92 0.76
Earnings Yield
(1.48%) (2.17%) (2.13%) 0.35%
Free Cash Flow Yield
5.24% 4.63% 3.40% 2.83%
Free Cash Flow per Share
1.18 (0.30) 3.09 4.34
Book value per Share
63.96 60.19 59.27 67.61
Free Cash Flow
58.57 (14.83) 148.62 207.28
EV/EBIT
469.42 155.10 147.77 102.83
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026